Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03762018 · OUTCOME

Disease Control (DC) at 24 Weeks

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From randomization to 24 weeks; participants assessed for treatment response status at 24 weeks.

What was measured

Disease Control (DC) is defined as complete or partial response, or disease stabilisation at 24 weeks (+/- 10 days). Patients with no available scan at this time period, but with scan performed before 24 weeks - 10 days and scan performed after 24 weeks + 10 days showing disease control, will be considered as disease control.

Analysis population: Efficacy population (Intention-To-Treat cohort of all randomised patients)

Groups in this outcome

Atezolizumab Plus Bevacizumab Plus Chemotherapy

Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Bevacizumab Plus Chemotherapy

Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab Plus Bevacizumab Plus Chemotherapy200
Bevacizumab Plus Chemotherapy200

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Bevacizumab Plus Chemotherapy134Not reportedNot reportedNot reportedNot reported
Bevacizumab Plus Chemotherapy115Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        134
      2. group Id
        OG001
        value
        115
denoms
  1. counts
    1. group Id
      OG000
      value
      200
    2. group Id
      OG001
      value
      200
    units
    Participants
description
Disease Control (DC) is defined as complete or partial response, or disease stabilisation at 24 weeks (+/- 10 days). Patients with no available scan at this time period, but with scan performed before 24 weeks - 10 days and scan performed after 24 weeks + 10 days showing disease control, will be considered as disease control.
groups
  1. description
    Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG000
    title
    Atezolizumab Plus Bevacizumab Plus Chemotherapy
  2. description
    Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG001
    title
    Bevacizumab Plus Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
Efficacy population (Intention-To-Treat cohort of all randomised patients)
reporting Status
POSTED
time Frame
From randomization to 24 weeks; participants assessed for treatment response status at 24 weeks.
title
Disease Control (DC) at 24 Weeks
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice